Dr. Reddy's
As of the edition of 20 October 2026, Dr. Reddy's runs 35 drugs, 23 of them marketed; it is on route A at 0 targets and on route B at 6 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 6 company names in this family.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 23 |
| Active | 1 |
| Went quiet | 9 |
| Stopped | 1 |
| Status not established | 1 |
| Total | 35 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Cyclophosphamide anhydrous | none listed | 0 |
| Bortezomib | none listed | 1 |
| Nicotine | none listed | 1 |
| Celecoxib | none listed | 2 |
| Amlodipine | none listed | 16 |
| Bendamustine | Ends 2029 (patent) | 0 |
| Minocycline | none listed | 0 |
| Heparin | none listed | 5 |
| Phenylephrine | none listed | 6 |
| Trimethoprim | none listed | 0 |
| Palonosetron | none listed | 3 |
| Sumatriptan | none listed | 1 |
| Guanfacine | none listed | 12 |
| Erythromycin | none listed | 0 |
| Ephedrine | none listed | 9 |
| Betamethasone dipropionate | none listed | 3 |
| Clobetasol propionate | none listed | 2 |
| Isosorbide mononitrate | none listed | 4 |
| Heparin sodium | none listed | 3 |
| Sulfadiazine | none listed | 0 |
| Sodium lauryl sulfate | none listed | 0 |
| Abametapir | none listed | 0 |
| Acebutolol | none listed | 1 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 6 targets.
All 6 rows on route A or B
In the product6 company-target rows on route A or B; 3 are not shown here, and no score is.
See all 6 targets where Dr. Reddy's needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Skin and connective tissue: 12 trials led
- Infections: 6 trials led
- Cancer: 3 trials led